Home / Research / Publications / Expression of novel immunotherapeutic targets in triple-negative breast cancer

Publications

Back

Expression of novel immunotherapeutic targets in triple-negative breast cancer

May 2014

– Caris Life Sciences

Presentation

Learning Objectives

Discuss immune checkpoints and their ramifications in human cancers
Evaluate the presence of PD-L1 expression in a large breast cancer population
Identify immune and molecular pathway associations with PD-L1
Review preliminary validation data

Download Publication

Discover
More

Learn More

Ready to Get Started on the Journey?

Name(Required)

First Last

Company/Institution(Required)

Role/Title(Required)

Email(Required)

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Caris Life Sciences Exceeds 1,000 Published Studies Milestone

Caris Life Sciences Appoints Dr. James Hamrick as Chairman of the Caris Precision Oncology Alliance

Publications

Expression of novel immunotherapeutic targets in triple-negative breast cancer

Discover
More

Ready to Get Started on the Journey?

Caris Life Sciences Exceeds 1,000 Published Studies Milestone

Caris Life Sciences Appoints Dr. James Hamrick as Chairman of the Caris Precision Oncology Alliance

Publications

Expression of novel immunotherapeutic targets in triple-negative breast cancer

DiscoverMore

Spliceosome Mutations in Metastatic Breast Cancer An Analysis of a Decentralized Clinical Trial and Large Clinical Genomic Dataset

Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC)

Ready to Get Started on the Journey?

Discover
More